Roy Beveridge, MD

home / authors / roy-beveridge-md

Articles

A panel of 4 experts on CLL

August 19th 2024

Future Directions of BTK Inhibitors in Leukemia and Lymphoma

Ryan Haumschild, PharmD, MS, MBA, CPEL Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

Experts discuss future directions of BTK inhibitors.

A panel of 4 experts on CLL

August 19th 2024

Patient Access Advocacy for BTK Inhibitors

Ryan Haumschild, PharmD, MS, MBA, CPEL Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

A panel of specialists discuss patient access advocacy for BTK inhibitors.

A panel of 4 experts on CLL

August 12th 2024

The Inflation Reduction Act: Implications for Patient Access in CL

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

A group of experts discuss implications for patient access in CLL.

A panel of 4 experts on CLL

August 12th 2024

Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers 

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

A panel of experts discuss navigating access challenges in CLL treatment.

A panel of 4 experts on CLL

August 5th 2024

Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

Experts discuss financial challenges of BTK inhibitor therapy.

A panel of 4 experts on CLL

August 5th 2024

Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

A panel of experts discuss combination regimens with BTK inhibitors.

A panel of 4 experts on CLL

July 29th 2024

Decision-Making in CLL: The Role of Real-World Evidence

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

A discussion on therapeutic decision-making in CLL and the role of real-world evidence.

A panel of 4 experts on CLL

July 29th 2024

Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.

A panel of 4 experts on CLL

July 23rd 2024

Optimizing Therapy Sequencing in CLL

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

A panel of experts discuss optimizing therapy sequencing in CLL.

A panel of 4 experts on CLL

July 23rd 2024

Empowering Patients: Key Considerations for BTK Inhibitor Adherence

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

A conversation on how to empower patients and the considerations for BTK inhibitor adherence.

A panel of 4 experts on CLL

July 12th 2024

Factors Influencing Choice of Second-Generation BTKi Monotherapy

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

Specialists discuss factors influencing the choices of second-generation BTK monotherapy.

A panel of 4 experts on CLL

July 12th 2024

Evaluating Value of BTK Inhibitors in CLL Treatment

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

Experts evaluate the value of BTK inhibitors in CLL treatment.

A panel of 4 experts on CLL

June 28th 2024

CLL Treatment Landscape: Overview of BTK Inhibitors

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

A panel of experts provide an overview of BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia.

A panel of 4 experts on CLL

June 28th 2024

Recent Trends and Innovations in the Management of CLL

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

Experts on the treatment of chronic lymphocytic leukemia discuss recent trends and innovations in the therapeutic landscape.

March 31st 2015

Cost Differential by Site of Service for Cancer Patients Receiving Chemotherapy

Jad Hayes, MS, ASA, MAAA J. Russell Hoverman, MD, PhD Matthew E. Brow, BA Dana C. Dilbeck, BA Diana K. Verrilli, MS Jody Garey, PharmD Janet L. Espirito, PharmD Jorge Cardona, BS Roy Beveridge, MD

The cost of care for patients receiving chemotherapy in community oncology clinics is lower than for comparable patients receiving chemotherapy in the hospital outpatient setting.

Latest Updated Articles

FDA approval stamp | Image Credit: Surendra - stock.adobe.com

Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

What We’re Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Program for Elderly Care; Health Care Not a Top Issue Among Voters

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Clinician giving patient a diagnosis | Image Credit: Pcess609 - stock.adobe.com

Published: October 21st 2024 | Updated: October 24th 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Hurricane | Image credit: Satoshi Kina - stock.adobe.com

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Opdivo packaging | Image credit: Bristol Myers Squibb

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

Published: November 1st 2024 | Updated: November 21st 2024

Table Multiple Myeloma Trials November 2024

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions